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Abstract
Background: The antiphospholipid syndrome (APS), characterised by recurrent miscarriage and thrombosis, is a
significant cause of morbidity and mortality. Domain I (DI) of human beta 2 glycoprotein I (β2GPI) is thought to contain
crucial antibody binding epitopes for antiphospholipid antibodies (aPL), which are critical to the pathogenesis of APS.
Expressing this protein in bacteria could facilitate studies investigating how this molecule interacts with aPL.
Methods: Using a computer programme called Juniper, sequentially overlapping primers were designed to be used in a
recursive polymerase chain reaction (PCR) to produce a synthetic DI gene. Specifically Juniper incorporates 'major'
codons preferred by bacteria altering 41 codons out of 61. This was cloned into the expression plasmid pET(26b) and
expressed in BL21(DE3) Escherichia coli (E. coli). By virtue of a pelB leader sequence, periplasmic localisation of DI aided
disulphide bond formation and toxicity was addressed by tightly regulating expression through the high stringency T7lac
promoter.
Results: Purified, soluble his-tagged DI in yields of 750 µg/L bacterial culture was obtained and confirmed on Western
blot. Expression using the native human cDNA sequence of DI in the same construct under identical conditions yielded
significantly less DI compared to the recombinant optimised sequence. This constitutes the first description of
prokaryotic expression of soluble DI of β2GPI. Binding to murine monoclonal antibodies that recognise conformationally
restricted epitopes on the surface of DI and pathogenic human monoclonal IgG aPL was confirmed by direct and indirect
immunoassay. Recombinant DI also bound a series of 21 polyclonal IgG samples derived from patients with APS.
Conclusion: By producing a synthetic gene globally optimised for expression in E. coli, tightly regulating expression and
utilising periplasmic product translocation, efficient, soluble E. coli expression of the eukaryotic protein DI of β2GPI is
possible. This novel platform of expression utilising pan-gene prokaryote codon optimisation for DI production will aid
future antigenic studies. Furthermore if DI or peptide derivatives of DI are eventually used in the therapeutic setting
either as toleragen or as a competitive inhibitor of pathogenic aPL, then an E. coli production system may aid cost-effective
production.
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The APS is a multi-system autoimmune disease character-
ised by vascular thrombosis and/or recurrent pregnancy
loss in patients who test positive for either aPL or lupus
anticoagulant [1]. APS carries a significant burden of mor-
bidity and mortality [2] with long-term anticoagulation
being the only treatment with any proven benefit in
reducing recurrent thrombosis [3]. Since anticoagulation
carries an inherent risk of bleeding it is desirable to
develop alternative treatments that target aPL directly.
Patients with APS generally have high levels of serum IgG
aPL. Monoclonal and polyclonal IgG aPL have been
shown to be pathogenic and promote thrombosis in vivo
[4,5]. aPL from patients with thrombosis only bind phos-
pholipids (PL) in the presence of protein co-factors, of
which β2GPI has been studied the most extensively.
Understanding how these pathogenic aPL interact with
β2GPI at the molecular level could ultimately facilitate the
development of targeted therapies.
β2GPI contains five homologous domains [6] and
anchors to PL via domain V [7]. Using domain deletion
studies, in which β2GPI was produced with one or more
domains deleted, it was shown that the amino terminal
domain (DI) is particularly important for aPL binding,
suggesting that crucial aPL binding epitopes are contained
within this domain [8-10]. A compound based on DI is
currently being studied for possible use as a toleragen to
treat APS patients by inducing anergy in B lymphocytes
that produce aPL [11]. Clearly an efficient method of DI
production could enhance the scope for investigating the
antigenic role of DI and facilitate epitope mapping stud-
ies. An expression system in E. coli could offer such a tool.
Furthermore if DI is ultimately used therapeutically,
prokaryotic expression lends itself to large-scale cost-effi-
cient production.
E. coli is the most frequently used prokaryotic expression
system for production of heterologous proteins due to its
efficiency, cost-effectiveness and potential for high-level
production [12,13]. However, various properties of differ-
ent genes, their transcribed mRNAs and protein products
may preclude efficient eukaryotic protein expression in
bacteria. Current expression methods for DI use baculovi-
rus containing a cloned cDNA sequence of the DI gene to
infect Spodoptera frigiperda insect cells [14]. This method of
expression is relatively expensive, laborious and less ame-
nable to being scaled-up in comparison to prokaryotic
expression systems. Other than the formation of two
disulphide bonds, no other post-translational modifica-
tions such as glycosylation are necessary for biologically
active DI expression. Hence an established E. coli expres-
sion system could hold several significant advantages over
the currently available system of production.
There are no published reports of DI expression in E. coli.
Previous attempts to achieve this may have been unsuc-
cessful for a number of reasons. We hypothesise that these
reasons are related to E. coli codon bias against eukaryotic
codons, potential toxicity of DI to E. coli and the relative
difficulty of disulphide bond formation in the reducing
environment of bacterial cytoplasm. In this paper we have
addressed these problems and now report the first system
for expressing DI in E. coli. We have demonstrated the
binding properties of the expressed protein to murine
monoclonal anti-antibodies that recognise conforma-
tional epitopes on the surface of DI, to pathogenic human
monoclonal IgG aPL and to polyclonal IgG derived from
APS patients.
Synthetic gene encoding for DI of human β2GPIFigure 1
Synthetic gene encoding for DI of human β2GPI. The synthetic gene encodes for DI (underlined amino-acids) and an 
OmpA leader sequence. Codons were chosen for optimal expression of DI in E. coli by Juniper, altering 67% of the native 
sequence (boxed codons). Synthetic oligonucleotide primers are denoted by grey shading; oligonucleotides of the upper DNA 
sequence are read 5' to 3' (left to right) and the oligonucleotides of the lower DNA sequence are read 3' to 5' (left to right). 
Restriction sites are denoted in light grey font.Page 2 of 11
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Pan gene codon optimisation and tight regulation of 
expression are critical in ensuring efficient production of 
DI by E. coli
A synthetic gene encoding for DI was designed by the
Juniper programme. Six 60 mer overlapping oligonucle-
otide primers covering the length of DI were specifically
designed by Juniper to minimise non-specific annealing.
These primers were used in one-step recursive PCR [15] to
create a DI gene (figure 1). Importantly, Juniper incorpo-
rates codons used preferentially by E. coli, as the native
cDNA sequence of DI contains an abundance of codons
used rarely by E. coli [6]. Of the 61 codons present in the
native DI gene, 26 (43%) are used by E. coli at a frequency
of less than 1%. These rare codons are present in clusters
of between two to five codons in length. Hence one may
expect translational problems in E. coli with an abundant
mRNA species containing an excess of rare low tRNA
codons [16]. Even a single rare codon can have a deleteri-
ous effect on heterologous protein expression [17]. The
establishment of other eukaryotic protein expression sys-
tems in E. coli, utilising the same codon optimisation
principles, has been described elsewhere [17-19], but few,
to our knowledge, have targeted all codons amenable to E.
coli optimisation as we have done. It is planned for this
software (Juniper) to be freely available over the internet
in the near future and enquiries about this should be
addressed to the authors of this paper. The proposed web-
site is cited in the reference list.
The eukaryotic protein DI is toxic to E. coli. Even small
amounts of DI basal production resulted in cell death
necessitating tight regulation of expression using the T7lac
promoter [20] and the addition of 1% glucose to the
expression cultures [21]. When the cell cultures were
induced with 1 mM or 0.4 mM isopropylβ-D-thiogalacto-
side (IPTG), marked inhibition of cell growth occurred.
However, inducing with 0.1 mM IPTG resulted in approx-
imately 80% increase in OD600 values, suggesting that E.
coli can only sustain a certain level of DI production,
above which marked toxicity and cell death occurs. The
incorporated pelB leader sequence directed the expressed
target protein into the bacterial periplasmic compartment
facilitating the formation of disulphide bond formation
and hence correct folding of DI. Western blot analysis of
periplasmic fractions from cell cultures induced with no
IPTG, 0.1 mM IPTG, 0.4 mM IPTG and 1 mM IPTG indi-
cate that most expression of target protein is seen with cell
cultures induced with 0.1 mM IPTG, with some leakage of
DI into the culture supernatant (figure 2). Furthermore,
no target protein is seen in the uninduced control con-
firming the tight regulation of basal expression that this
system provides. We suggest that E. coli may be able to sus-
tain a critical level of DI production with gentle induction
at low IPTG concentrations, above which intolerable
amounts of rapid DI production result in marked E. coli
toxicity, leading to overall reduced yield of target protein.
In order to assess the contribution of using optimal
codons preferred by E. coli, we compared expression of the
synthetic bacterial gene with expression of human cDNA
encoding DI. This human DI cDNA, cloned into a BacPAK
plasmid, BD Biosciences (San Jose, CA, USA) was donated
as kind gift from M Iverson and M Linnik (LJP, San Diego,
USA). The human DI sequence was amplified using PCR
with primers designed to incorporate flanking NcoI and
XhoI restriction sites, which were used for ligation into
pET-26b(+). Parallel expression cultures of both con-
structs (each identical other than one containing the
native DI sequence and the other the synthetic DI
sequence designed by Juniper) were performed. Equal
amounts of periplasmic protein extracts from both cul-
tures were transferred onto a membrane. Western blot
analyses by probing with an anti-his5 antibody confirmed
significantly greater target protein production using the
synthetic gene (figure 3).
Recombinant periplasmic his-tagged DI is 
conformationally correct and may be purified using nickel 
chromatography
The presence of hexahistidine (his6)-tagged DI within
periplasmic samples was confirmed by performing West-
ern blot experiments probing the membrane with mAb-
16 and 6C4C10 murine anti-DI antibodies (figure 2) and
an anti-his5 antibody (figure 3). The murine anti-DI anti-
Optimum DI expression observed at lower levels of IPTG inductionFig re 2
Optimum DI expression observed at lower levels of 
IPTG induction. Western blot of expression cultures 
induced with 1 mM, 0.4 mM, 0.1 mM IPTG and an uninduced 
control. Both non-reduced periplasmic extracts (P) and 
supernatant (S) samples were analysed using 15% SDS-PAGE 
and transferred onto a membrane. The membrane was 
probed with 6C4C10, a monoclonal murine anti-DI antibody. 
All cultures were performed in parallel under identical condi-
tions and equal volumes applied to the protein gel. Greatest 
expression of DI was observed from cultures induced with 
0.1 mM IPTG.
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DI, recognize conformational epitopes of DI [22]. These
antibodies have been shown previously to bind non-
reduced DI on a Western blot but not to DI where the
cysteine residues have been blocked to prevent disulphide
bond formation. The fact that these antibodies bind
expressed non-reduced DI on both Western blot (figure 2)
and direct immunoassay (figure 4) suggests strongly that
our periplasmic product is folded correctly.
DI was purified using nickel chromatography utilising the
incorporated C-terminal his6-tag and eluted with 300 mM
imidazole. Purity of the eluted DI protein was assessed
using 15% SDS-PAGE after extensive dialysis against
phosphate buffered saline (PBS)-10% glycerol, in order to
remove the imidazole (figure 5). Yields of expressed solu-
ble DI approximated to 750 µg/L expression culture, as
assessed using the BCA protein assay.
Human IgG aPL binds to expressed DI
IS4 is a monoclonal aPL with proven in vivo thrombogenic
pathogenicity derived from a patient with APS [23]. Our
group have made two variants of this monoclonal aPL,
swapping the light chain (VL) with that of an anti-DNA
antibody B3 and another monoclonal aPL UK-4. We have
previously shown that the three expressed heavy/light
chain combinations IS4VH/IS4VL, IS4VH/B3VL and IS4VH/
UK-4VL possess different abilities to bind cardiolipin andβ2GPI [24,25]. We have established that replacing the VL
of IS4 with that of B3 (IS4VH/B3VL) increases binding to
cardiolipin and β2GPI whereas IS4VH/UK-4VL binds very
poorly to either antigen [24,25]. These three heavy/light
combinations show similar order of binding to DI in
direct enzyme-linked immunosorbent assay (ELISA) as
was previously seen in anti-cardiolipin and anti-β2GPI
ELISA (figure 6a and 6b) [24,25]. However, it was noted
that though IS4VH/UK-4VL bound DI to a lesser degree
than the other antibodies studied (figure 6b), the degree
of binding to DI of this antibody was much greater than
that observed to β2GPI (figure 6a) or cardiolipin [24,25].
These results suggest the presence of crucial antibody
binding epitopes that become exposed on the surface of
DI when it is not attached to the rest of the β2GPI mole-
cule. This notion is underlined by the inhibition assay
(figure 7), which demonstrates that expressed DI inhibits
binding of affinity purified native IS4 to DI more strongly
than equivalent µmol concentrations of whole β2GPI.
This data confirms the antigenicity of recombinant DI
expressed by E. coli in both solid and fluid phase assays.
Antigenicity studies of recombinant DI produced by E. coli
were expanded to test binding to a series of affinity puri-
fied polyclonal IgG samples derived from patients with
APS. 21 serum samples known to bind cardiolipin and
β2GPI from patients with APS were identified. The IgG
fraction was affinity purified using Protein G coated beads
and tested for binding to recombinant DI coated on a
nickel plate. We also tested purified IgG derived from two
sets of control subjects. There were nine healthy controls
and 14 subjects with systemic lupus erythematosus (SLE)
who did not have APS. SLE was chosen as a disease control
because it is a closely related autoimmune disease and SLE
and APS can co-exist in the same patient. Figure 8 shows
that binding of polyclonal IgG from patients with APS was
significantly greater than binding to polyclonal IgG from
either control group.
Clearly recombinant DI expressed by E. coli binds IgG
from patients with APS. The fact that DI binds IS4 better
than whole β2GPI in the fluid phase implies that recom-
binant DI may be used as a competitive inhibitor of the
pathogenic aPL/β2GPI interaction and thus act as a poten-
tial therapeutic agent. The ability to produce such an agent
by expression in E. coli would be advantageous. Given that
DI is produced in bacteria however sufficient measures
should be undertaken to ensure expressed samples are free
from lipopolysaccharide.
Greater expression of DI seen with gene optimised for E. coli expressionFigur  3
Greater expression of DI seen with gene optimised 
for E. coli expression. Western blot analyses of recom-
binant his6-tagged DI. Protein was transferred onto a nitro-
cellulose membrane from a 15%-SDS-PAGE gel and probed 
with an anti-his5 antibody. Lane 1, his6-tagged molecular 
weight protein markers; lane 2, DI expressed using the native 
cDNA human sequence; lane 3, DI expressed using sequence 
optimised for E. coli. Equal volumes of periplasmic extract 
were applied to lanes 1 and 2 on the protein gel.Page 4 of 11
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We have shown that, by using a stepwise strategy to
address specific problems relating to codon optimisation,
periplasmic protein translocation and tight regulation of
expression, efficient bacterial expression of DI of human
β2GPI is possible. Recombinant DI was conformationally
correct and bound human monoclonal aPL in both solid
and fluid phase assays. DI also bound a series of IgG sam-
ples derived from patients with APS. This is the first
description of DI production using an E. coli expression
system. Ease and efficiency of expression will be utilised to
study different epitopes on DI and investigate the binding
of variants of DI to polyclonal IgG affinity purified aPL
derived from patients with APS. Furthermore if DI or a
peptide derived from DI is eventually used in the thera-
peutic setting [11] an E. coli system of production would
be likely to facilitate production and cost.
Finally, we submit that the simple design and production
of a synthetic gene globally optimised for expression in E.
coli using Juniper and one-step recursive PCR, as illus-
trated in this paper, is an important technique that can be
applied to other eukaryotic proteins, particularly if the
cDNA sequences of these genes have clusters of codons
used infrequently by E. coli.
Methods
Materials
Oligonucleotide primers were synthesised by Thermobio-
sciences (Germany) and used without further purifica-
tion. Restriction enzymes NcoI, XhoI and BglII and T4
DNA ligase were purchased from Promega, (Southamp-
ton, UK). Plasmids pET-26b(+) and BL21(DE3) E. coli
cells were purchased from Novagen (Nottingham, UK).
DH5α E. coli cells were supplied by Gibco (Paisley, UK).
Automated sequencing was carried out by MWG-Biotech
(Ebensburg, Germany).
Monoclonal antibodies
Three human monoclonal antibodies (mAb) were pro-
duced in Chinese Hamster Ovary (CHO) cells, an in-vitro
expression system, which has been described in detail in
previous papers [25,26]. Affinity purification of the anti-
bodies from these cells was carried out by Chemicon
Direct ELISA of murine-anti DI antibodies binding wild-type recombinant his6-tag DIFigure 4
Direct ELISA of murine-anti DI antibodies binding wild-type recombinant his6-tag DI. 6C4C10 and mAb-16 bind 
conformational epitopes on DI. Binding of these antibodies to DI indicates that expressed recombinant DI is likely to be folded 
correctly.Page 5 of 11
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human DI antibodies mAb-16 and 6C4C10 were kind
gifts from Dr M Linnik and Dr M Iverson, La Jolla Pharma-
ceuticals (LJP), California, USA.
Production of a construct containing a synthetic gene 
encoding the DI sequence
A synthetic gene was designed to encode for DI of human
β2GPI, an N-terminal OmpA leader sequence and BglII/
NcoI flanking restriction sites. This gene was designed by
the computer programme Juniper, which designed six 60
mer overlapping oligonucleotide primers based on the
published amino acid sequence of DI [6]. The gene encod-
ing for DI was synthesised using these primers by recursive
PCR [15] (figure 1). Twenty pmol of each outer primer
and two pmol of each internal primer were used in a reac-
tion containing 2 U of Vent DNA polymerase (New Eng-
land Biolabs (NEB), Hertfordshire, UK) and 25 mM of 2'-
deoxynucleoside 5'-triphosphates (dNTPs') in 100 µl of
the 10× supplied buffer and ddH20. PCR was performed
under the following conditions: 95°C for 8 min, 30 cycles
of 94°C for 2 min, 57°C for 1 min, 72°C for 1 min with
a final extension step of 72°C for 10 min. This gene was
then ligated into the expression plasmid and sequenced to
exclude PCR errors.
The pET system originally described by Studier and Moffat
[27] was used to express recombinant DI. A variety of con-
structs were used to optimise expression. The final cloned
expression construct encoded for a pelB leader sequence
followed by DI and a C-terminal his6-tag cloned into pET-
26b(+). Both the leader and the his6-tag are present within
the pET-26b(+) plasmid so that the OmpA leader sequence
that had originally been created by recursive PCR (figure
1) was redundant and removed at this stage. The target
gene was under the control of the high stringency phage
T7lac promoter [20] and a strong T7 translation initiation
site.
Induction experiments
The final recombinant expression vector pET26b(+), con-
taining the DI gene and a kanamycin resistance gene, was
transferred to the expression strain BL21(DE3). Single col-
onies were picked from the transformants, and 5-ml cul-
tures prepared in 50-ml falcons (overnight with shaking,
30°C). Fresh 500-ml cultures in 2.5-litre flasks were then
set up using the overnight culture to inoculate the
medium to an optical density (OD)600 of 0.1. Cultures
were induced with a range of IPTG (0.1 mM, 0.4 mM or 1
mM) at an OD600 of 0.6 and allowed to grow for a further
4 hours (30°C, shaking). 'Terrific' broth containing 60 µg/
ml of kanamycin was used to prepare the overnight cul-
tures with the addition of 1% glucose for the expression
cultures. OD600 was recorded at periodic intervals before
and after induction as a measure of bacterial growth in the
culture.
Preparation of periplasmic fraction and purification
The method for periplasmic extraction of protein from E.
coli is based on previously published methods by our
group for the expression of periplasmic Fabs of human
autoantibodies in W3110 E. coli [28]. Briefly, cultures
were spun (4000 g, 20 min, 4°C) following 4 hours
induction and supernatant was saved (at 4°C) for the
detection of any leaked DI protein from the cells. The cell
pellet was then exposed to osmotic shock by suspension
in ice-cold water (30 ml of dH20 per litre of culture),
stirred for 30 min at 4°C, and spun (8000 g, 20 min,
4°C). This supernatant constitutes the periplasmic frac-
tion containing recombinant DI, an aliquot of which was
stored at -20°C for subsequent SDS-PAGE and Western
blot analysis.
For purification periplasmic extract was loaded on a col-
umn containing nickel charged resin, Novagen (Notting-
ham, UK). DI bound to the column by virtue of the C-
terminal his6-tag and was eluted with 300 mM imidazole,
(2 M NaCl, 80 mM Tris-HCl, pH 7.9). Recombinant his6-
tagged DI was then dialysed extensively against PBS-10%
glycerol overnight at 4°C using dialysis visking tubing,
MWCO-3500, Medicell (London, UK). The purity of the
eluted DI was assessed on SDS-PAGE 15% gels.
Functional assessment
Affinity purification of IgG aPL
Polyclonal IgG was purified from 21 patients satisfying
the preliminary diagnostic criteria for APS [1]. IgG was
DI purification using nickel chromatographyFigure 5
DI purification using nickel chromatography. Samples 
analysed by 15% SDS-PAGE. Lane 1, protein molecular 
weight marker; lane 2, periplasmic extract; lane 3, flow-
through from nickel column; lane 4, wash with 5 mM imida-
zole; lane 5, wash with 45 mM imidazole; lane 6, elution with 
300 mM imidazole.
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Recombinant DI binds monoclonal human aPL with the same order of binding as seen with whole β2GPIFigure 6
Recombinant DI binds monoclonal human aPL with the same order of binding as seen with whole β2GPI. ELISA 
of β2GPI (fig. 6a) and his6-tagged DI (fig. 6b) binding to IS4VH/B3VL. IS4VH/IS4VL and IS4VH/UK-4VL. The same order of binding 
of aPL to both β2GPI and DI was observed. Greatest binding was seen with IS4VH/B3VL and least with IS4VH/UK-4VL.
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SLE (but no APS) as disease controls. 19/21 patients with
APS, 13/14 patients with SLE and 7/10 healthy controls
were female. The mean ages of the subjects in the three
groups were comparable (APS – 44.0 years, SD 7.0; SLE
37.2 years, SD 10.0; healthy controls 33.2 years, SD 9.0).
Ethical approval for the study was granted by University
College London Hospital Research Ethics Committee.
Protein G beads (Amersham, Bucks, UK) were prepared
by washing with PBS. 1 ml serum was mixed with 2 mls
0.02 M sodium phosphate (pH 7) binding buffer and
incubated at room temperature (RT) for two hours with
0.5 ml prepared Protein G beads. This mixture was then
spun (200 g, 5 min, 4°C) and the beads washed a further
3 times with binding buffer. Elution of IgG from the beads
was performed by mixing the beads with 2 mls 0.1 M gly-
cine (pH 2.7) for 1 min. This was spun (200 g, 5 min,
4°C) and the supernatant stored as the IgG fraction at -
20°C. The amount of IgG was quantified using a direct
IgG ELISA described in a previous paper [25].
Direct binding ELISA of aPL binding to purified recombinant his6-
tagged DI
Nickel chelate-coated microwell plates, VH Bio (Gates-
head, UK) were coated with 50 µl of recombinant purified
his6-tagged DI and diluted to a concentration of 50 µg/ml
using PBS. One half of the plate (the test wells) was coated
with DI and the other half with PBS (the control wells).
Plates were incubated at RT for 2 hours and were then
washed three times with PBS, blocked with 100 µl of
0.25% gelatin, Sigma (Poole, UK) in PBS and incubated
for a further 1 hour at RT. After washing the plates three
times with PBS, 50 µl of a monoclonal human IgG aPL
(IS4VH/IS4VL, IS4VH/B3VL or IS4VH/UK-4VL) derived from
CHO cell culture supernatant [24] in sample, enzyme and
conjugate dilution (SEC) buffer (100 mM Tris-HCl (pH
7), 100 mM NaCl, 0.02% Tween-20 and 0.2% BSA) was
Recombinant DI in solution is an effective inhibitor of a pathogenic monoclonal human aPL in vitroFigure 7
Recombinant DI in solution is an effective inhibitor of a pathogenic monoclonal human aPL in vitro. Competitive 
inhibition of affinity purified IS4VH/IS4VL binding to his6tagged-DI bound to a nickel chelate plate, by recombinant DI and wild 
type β2GPI as inhibitors. A constant amount of antibody was mixed with varying concentrations of inhibitor and allowed to 
equilibrate at room temperature. For a given µmol concentration of inhibitor, DI alone is a more effective inhibitor of IS4VH/
IS4VL than whole β2GPI.Page 8 of 11
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ml. Serial dilutions of mAb were loaded such that for each
dilution loaded in a test well, there was a corresponding
control well loaded with the same dilution. For polyclo-
nal IgG aPL purified from APS patients, SLE and normal
controls, 50 µl of 20 µg/ml of IgG in SEC buffer was added
to each well. Binding of human antibodies to the plate
was detected by adding goat anti-human IgG alkaline
phosphatase conjugate, Sigma (Poole, UK) diluted
1:2000 in SEC. After incubation at 37°C for 1 hour,
bound antibody was detected by addition of alkaline
phosphatase chromogenic substrate. The OD was meas-
ured in a Genios microplate autoreader (Tecan, Reading,
UK). A net OD was calculated for each well to take into
account background (OD test well – OD control well).
Results of polyclonal IgG were expressed as a percentage
binding of a standard APS patient sample known to bind
DI, whole β2GPI and CL.
Competitive inhibition ELISA
A direct binding ELISA carried out as above was used to
determine the concentration of native affinity purified
antibody IS4VH/IS4VL required to achieve ~50% maxi-
mum binding. This concentration was 200 ng/ml. DI and
β2GPI as test inhibitors were diluted in PBS at concentra-
tions ranging from 0 (i.e. no inhibitor) to 30 µM. Affinity-
purified IS4VH/IS4VL was then added to each concentra-
tion of inhibitor to achieve 200 ng/ml final concentration
Recombinant DI binds purified aPL derived from patients with APSFigure 8
Recombinant DI binds purified aPL derived from patients with APS. Results are expressed as percentage binding of a 
standard APS IgG sample known to bind DI, whole β2GPI and CL. IgG was purified from 21 APS patients, 14 SLE patients and 9 
normal controls. 20 µg/ml of IgG of each individual patient sample was tested for binding to DI and compared to the standard. 
Binding to DI was significantly greater in the APS group compared to SLE disease control and normal control groups (Student's 
t-test analysis (paired, 2-tailed) – APS versus SLE, **p < 0.005; APS versus normal controls, **p < 0.005; SLE versus normal 
controls p = 0.2).
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BMC Biotechnology 2006, 6:8 http://www.biomedcentral.com/1472-6750/6/8of antibody for each sample. The samples were incubated
at RT for 2 hours and then tested for binding to DI on an
ELISA plate as described earlier for the direct ELISA above.
The per cent inhibition for each concentration of inhibitor
was determined from the following formula:
% inhibition=(A0-A/A0) × 100, where A is the OD from
the well containing the inhibitor (corrected for back-
ground) and A0 is the OD from the well containing no
inhibitor (corrected for background).
Abbreviations
β2GPI, beta 2 glycoprotein I; aPL, antiphospholipid anti-
bodies; APS, antiphospholipid syndrome; DI, domain I;
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